# Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

> **NCT01869764** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 57 (actual)

## Conditions studied

- Ductal Breast Carcinoma in Situ
- Lobular Breast Carcinoma in Situ
- Male Breast Cancer
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **DRUG:** omega-3 fatty acid
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01869764
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2019-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01869764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01869764, "Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01869764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*